reSee.it - Related Video Feed

The speaker discusses the devastating impact of the deaths caused by the current situation. They anticipate that this will shift the focus of research and development budgets towards addressing the lack of vaccines that can effectively block transmission. While current vaccines help improve individual health, they only offer limited reduction in transmission. The speaker emphasizes the need for a new approach to vaccine development.

The discussion centers on gain-of-function (GoF) research, its regulation, and the motivations behind it. The first speaker notes the administration’s goal to end GoF research and asks where that stands. The second speaker says progress has been made, and the White House is working on a formal policy. He then defines the issue in stages: what GoF research is, why someone would do it, and how to regulate it to prevent dangerous projects that could catastrophically harm human populations. He clarifies that GoF research is not inherently bad, but dangerous GoF research is. He gives an insulin example: creating bacteria to produce insulin is a legitimate GoF that benefits diabetics. In contrast, taking a virus from bat caves, bringing it to a lab in a densely populated city with weak biosafety, and manipulating it to be more transmissible among humans is a dangerous GoF that should not be supported. The administration’s policy aims to prevent such dangerous work entirely, and the President signed an executive order in April or May endorsing this policy. Next, he discusses implementation: how to create incentives to ensure this research does not recur. He explains that the utopian idea behind such research was to prevent all pandemics by collecting viruses from wild places, testing their potential to infect humans by increasing their pathogenicity, and then preparing countermeasures in advance (vaccines, antivirals) and stockpiling them, even though those countermeasures would not have been tested against humans yet. If a virus did leap to humans, the foreseen countermeasures might prove ineffective because evolution is unpredictable. This “triage” approach—identifying pathogens most likely to leap and preemptively preparing against them—was the rationale for dangerous GoF work, a rationale he characterizes as flawed. He notes that many scientists considered this an effort to do bioweapons research under the guise of safety and defense. The work is dual-use. The U.S. is a signatory to the Biological Weapons Convention and does not conduct offensive bio-weapons research, but other countries might. The discussion highlights that the GoF research discussed during the pandemic can backfire and may not align with true biodefense, since countermeasures might not match whatever pathogen actually emerges. The speaker concludes that this agenda—pursuing GoF to prevent pandemics—has drawn substantial support from parts of the Western world and other countries for about two and a half decades, but he implies it is not deserving of continuation.

The video discusses various topics related to biotechnology, biomedical technology, and the potential risks associated with biological weapons. It mentions the use of nanotechnology, the development of vaccines, and the role of international cooperation in addressing these issues. The speakers also touch on the possibility of synthetic viruses and the need for ethical governance in research and implementation. Overall, the video emphasizes the importance of understanding and managing the risks associated with biotechnology for the benefit of society.

The speaker discusses the devastating impact of the deaths caused by the current situation. They anticipate that this will shift the focus of research and development budgets towards addressing the lack of vaccines that can effectively block transmission. While current vaccines help improve individual health, they only offer limited reduction in transmission. The speaker emphasizes the need for a new approach to vaccine development.

A meeting occurred in June involving biopharma, the military, DARPA, and ASPR, focusing on medical countermeasures. The DOD is planning for a future event, allowing biopharma companies to manufacture countermeasures before FDA approval, similar to how COVID shots were stockpiled. The meeting, titled "Partnering with US government to achieve our national security mission," indicates a planned public health threat that will impact national security. The aim is to advance defense readiness through DOD partnerships for rapid development and deployment of medical countermeasures. AI will be used without safety or efficacy testing, creating dual-use products that could be weaponized. Laws have been rewritten, making the PREP Act seem minor in comparison, potentially deputizing police or doctors as DOD employees. Deployment methods may include spraying schools, cruise ships, or communities, or using transdermal patches, not just injections. DARPA has been funding dual-use products, turning military bioweapons into an industry.

The speaker discusses the devastating impact of the deaths caused by the current situation. They predict that this will lead to a shift in research and development budgets towards addressing the lack of vaccines that can effectively block transmission. While current vaccines help with individual health, they only offer limited reduction in transmission. The speaker emphasizes the need for a new approach to vaccine development.

The speaker emphasizes the complexity of the issue, stating that the health sector alone cannot solve it. Collaboration with other departments like Homeland Security and NATO is necessary. They stress the importance of countering anti-vaccine aggression, highlighting the impact of such beliefs on public health.

Project BioShield is a proposed initiative to enhance future security against bioterrorism. The speaker requests support for a budget proposal of almost $6,000,000,000. This funding aims to rapidly develop and provide effective vaccines and treatments. The focus is on agents like anthrax, botulinum toxin, Ebola, and plague. The speaker asserts the necessity to act preemptively, based on the assumption that enemies may weaponize these diseases.

To create a defensive program against bioterrorism, the speaker consulted with unconventional sources. These included former U.S. bioweapons experts from decades ago, international figures from countries like the U.K., and defectors from the Soviet Union. The speaker learned from these experts to inform the development of a multi-billion dollar program.

The speaker, who has served in 5 administrations, discusses the issue of pandemic preparedness. They emphasize that the coming administration will face challenges in dealing with infectious diseases, including both chronic diseases and surprise outbreaks. The speaker highlights the importance of learning from past experiences, such as HIV, and stresses the need for substantial resources, involvement of communities, cross-sector collaboration, and engagement of leaders and policymakers. They assert that infectious diseases are a perpetual challenge that will not go away, and confidently state that such challenges will be seen in the next few years.

The speakers discussed the constant hacks that caused disruptions and the need for better protection against future threats. They suggested that studying the origins of outbreaks should become a routine practice, with experts reviewing each outbreak. They also emphasized the importance of joint studies and collaboration among scientists worldwide. The speakers believed that making these measures routine would help prevent and combat future outbreaks.

We used to defend against a known list of chemical and biological threats, but now we face new challenges. Global warming is causing the permafrost to melt, revealing forgotten pathogens. Additionally, our adversaries have advanced technologies that expand the definition of biodefense beyond known threat agents. To address these changes, the Department of Defense is forming a council that will involve combatant commands, services, and other components. Working groups will be established to tackle the complex policy and strategy challenges and prioritize efforts. These bodies will shape the biodefense environment within the department.

The speaker discusses the devastating impact of the deaths caused by the current situation. They anticipate that this will shift the focus of research and development budgets towards addressing the lack of vaccines that can effectively block transmission. While current vaccines offer some health benefits, they only provide limited reduction in transmission. The speaker emphasizes the need for a new approach to vaccine development.

The video discusses the importance of modernizing weapon systems and addressing vulnerabilities to cyber attacks. It emphasizes the need for network security solutions and highlights the role of electronic warfare in manipulating the human body. The speaker urges transparency about these practices and encourages research into biofield connections.

I will discuss pandemic preparedness today. Based on my experience, I can say that the next administration will face challenges with chronic infectious diseases and unexpected outbreaks. In my 32 years as NIAID director, history shows that these challenges are inevitable for the new administration.

All components involved in global or targeted responses will come together in this new initiative. Working groups will address the complex policy and strategy challenges, as well as prioritize future efforts. The Department of Defense and the biodefense enterprise will have ad hoc or evergreen bodies to shape the environment.

The speaker discusses the importance of the Bioposture Review (BPR) and the need for active US government engagement in biodefense. They mention the appointment of new leadership, the creation of a Biodefense Council, and the need for better biosafety and biosecurity. The BPR addresses bio threats from various sources, including natural, man-made, and accidental, and emphasizes the importance of international cooperation. The speaker also highlights the role of the Department of Defense (DoD) in supporting civilian efforts during the COVID-19 pandemic and other bio threats. They mention the need for ongoing reviews and the establishment of working groups to address policy and strategy challenges in biodefense. The speaker concludes by discussing the funding request for biodefense initiatives.

There is a concern about the potential for a big war or a natural pandemic, which could cause millions of deaths. The last major pandemic happened a century ago, but with the speed of global travel, the spread of a pandemic could happen quickly. However, the speaker is most worried about bioterrorism. They believe that even a small terrorist group could cause significant harm using non-human to human transmissible agents like anthrax. Thankfully, these groups have not yet been able to obtain or create a nuclear weapon.

The speaker argues that confronting future pandemics requires the development and integration of several new tools and capabilities, implemented continuously so societies are never caught off guard again. A central element is environmental surveillance conducted on an ongoing basis, forming a persistent early-warning system that can detect emerging threats before they escalate. A second key capability is the ability to produce diagnostics at an unprecedented scale: literally billions of diagnostics within a few months, with the combination of very low cost and high accuracy. The implication is that rapid, widespread testing would be feasible, enabling quick identification and response to infectious threats and reducing the chance of uncontrolled spread. Third, the speaker emphasizes the need for a worldwide network of vaccine manufacturing capacity. This network should include mRNA vaccine factories at multiple levels of capacity, designed to operate at very low cost and capable of producing vaccines that are affordable for broad populations. The emphasis is on creating scalable, geographically distributed production to ensure rapid deployment of vaccines during health emergencies. The speaker notes that recent advances funded by various foundations and organizations are enabling these capabilities, particularly in establishing such vaccine manufacturing infrastructure. These advances are described as enabling the global network to be established and to function efficiently when a new threat emerges. When these elements—surveillance, a global health core, diagnostics, antibody capacities, and other related capabilities—are integrated, the speaker asserts that if a pathogen like COVID-19 were faced again, the response would be dramatically better. The proposed combination of continuous monitoring, mass diagnostic production, and distributed vaccine manufacturing is presented as the key to substantially improving outcomes in future pandemics. Finally, the speaker asserts an aspirational outcome: every country should perform better in a future pandemic than even the very best countries did in the past. This sets a benchmark for international preparedness and underscores the belief that the described toolkit—surveillance, diagnostics, manufacturing capacity, and allied resources—can elevate global response to levels that surpass current best practices.

The speaker discusses the devastating impact of the deaths caused by the current situation. They predict that this will result in a shift in research and development budgets towards addressing the lack of vaccines that can effectively block transmission. While current vaccines help improve individual health, they only offer limited reduction in transmission. The speaker emphasizes the need for a new approach to vaccine development.

The speaker discusses the devastating impact of the deaths caused by the current situation. They anticipate that this will shift the focus of research and development budgets towards addressing the lack of vaccines that can effectively block transmission. While current vaccines help improve individual health, they only offer limited reduction in transmission. Therefore, the speaker emphasizes the need for a new approach to vaccine development.

The speaker believes mRNA shots are a "festering wound" impacting everyone that cannot be ignored. The speaker urges the new administration to address the issue, citing 500 mRNA shots in the pipeline, 33 of which are self-amplifying. Self-amplifying means they are designed to replicate indefinitely, which the speaker finds "terrifying" because current mRNA shots already lack an "off switch." The speaker claims these self-amplifying shots are already in use in Japan, India, and the EU. The speaker believes the one in the US pipeline is for H1N1, so it may not be used unless there is an issue, but they are still experimenting with it.

The speaker discusses the importance of biodefense and the need to prioritize it beyond just the context of COVID-19. They highlight the need to prevent the acquisition of dangerous pathogens and maintain the capability to control outbreaks in the event of a biological attack. The speaker mentions the inaugural biodefense posture review and efforts to align with the national defense strategy. They emphasize the need for collaboration and integration across departments, agencies, and allies. The speaker also discusses the evolving threat landscape, the importance of biosurveillance, and the concept of integrated layered defense. They mention the development of non-specific medical countermeasures and advancements in drug development. The speaker concludes by emphasizing the need for cohesion, coordination, and collaboration within the biodefense community.

The speaker discusses the need for an effective incapacitating agent that can be deployed locally using drones or aerosol delivery technology. They emphasize the preference for antibody and drug therapeutics over vaccines. The ideal scenario involves using an incapacitating agent that can be inhaled and gives encephalitis, while having a mitigation strategy for their forces that lasts for about a month. This would allow them to move into the field of operation without worrying about the enemy. The speaker also mentions the classified nature of this technology and believes there is more happening than what is publicly known.